Differential expression of somatostatin receptor subtype 1-5 proteins in numerous human normal tissues

Experimental and Clinical Endocrinology and Diabetes

Volumn 120, Issue 8, 2012, Pages 482-489

  Unger, N ^a   Ueberberg, B ^a   Schulz, S ^b   Saeger, W ^c   Mann, K ^a   Petersenn, S ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c Marienhospital Stuttgart   (Germany)

Author keywords

immunohistochemistry; physiology; regulation; sst1 5

Indexed keywords

POLYCLONAL ANTIBODY; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ADENOHYPOPHYSIS; ADRENAL CORTEX; ARTICLE; BONE MARROW CELL; CORPUS LUTEUM; GRANULOPOIESIS; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEYDIG CELL; MEDULLA OBLONGATA; NORMAL HUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; TESTIS;

ADRENAL CORTEX; FEMALE; GRANULOSA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; ISLETS OF LANGERHANS; MALE; ORGAN SPECIFICITY; PITUITARY GLAND, ANTERIOR; PROTEIN ISOFORMS; RECEPTORS, SOMATOSTATIN; TESTIS; THYROID GLAND;

EID: 84866006612     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0032-1314859     Document Type: Article

References (57)

1. Patel Y C. Somatostatin and its receptor family. Front Neuroendocrinol: 1999; 20 157 198
2. Bruns C, Raulf F, Hoyer D et al. Binding properties of somatostatin receptor subtypes. Metabolism: 1996; 45 17 20
3. Freda P U. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab: 2002; 87 3013 3018
4. Oberg K, Kvols L, Caplin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol: 2004; 15 966 973
5. Bruns C, Lewis I, Briner U et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol: 2002; 146 707 716
6. Unger N, Serdiuk I, Sheu S Y et al. Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours. Clin Endocrinol (Oxf): 2008; 68 850 857
7. Schulz S, Handel M, Schreff M et al. Localization of five somatostatin receptors in the rat central nervous system using subtype-specific antibodies. J Physiol Paris: 2000; 94 259 264
8. Schulz S, Schulz S, Schmitt J et al. Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res: 1998; 4 2047 2052
9. Schulz S, Pauli S U, Schulz S et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res: 2000; 6 1865 1874
10. Kumar U, Sasi R, Suresh S et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes: 1999; 48 77 85
11. Le Romancer M, Cherifi Y, Levasseur S et al. Messenger RNA expression of somatostatin receptor subtypes in human and rat gastric mucosae. Life Sci: 1996; 58 1091 1098
12. Pfeiffer M, Koch T, Schroder H et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem: 2001; 276 14027 14036
13. Pfeiffer M, Koch T, Schroder H et al. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem: 2002; 277 19762 19772
14. Schulz S, Schmidt H, Handel M et al. Differential distribution of alternatively spliced somatostatin receptor 2 isoforms (sst2A and sst2B) in rat spinal cord. Neurosci Lett: 1998; 257 37 40
15. Schulz S, Helmholz T, Schmitt J et al. True positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of sst2A and sst5. Breast Cancer Res Treat: 2002; 72 221 226
16. Schulz S, Schmitt J, Quednow C et al. Immunohistochemical detection of somatostatin receptors in human ovarian tumors. Gynecol Oncol: 2002; 84 235 240
17. Mundschenk J, Unger N, Schulz S et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab: 2003; 88 5150 5157
18. Kulaksiz H, Eissele R, Rossler D et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut: 2002; 50 52 60
19. Lupp A, Hunder A, Petrich A et al. Reassessment of sst(5) Somatostatin Receptor Expression in Normal and Neoplastic Human Tissues Using the Novel Rabbit Monoclonal Antibody UMB-4. Neuroendocrinology: 2011; 94 255 264
20. Rohrer S P, Birzin E T, Mosley R T et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science: 1998; 282 737 740
21. Rossowski W J, Coy D H. Specific inhibition of rat pancreatic insulin or glucagon release by receptor-selective somatostatin analogs. Biochem Biophys Res Commun: 1994; 205 341 346
22. Mercado M, Borges F, Bouterfa H et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf): 2007; 66 859 868
23. Schopohl J, Strasburger C J, Caird D et al. Efficacy and acceptability of lanreotide Autogel(R) 120mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes: 2011; 119 156 162
24. Kreienkamp H J, Akgun E, Baumeister H et al. Somatostatin receptor subtype 1 modulates basal inhibition of growth hormone release in somatotrophs. FEBS Lett: 1999; 462 464 466
25. Petersenn S, Schopohl J, Barkan A et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab: 2010; 95 2781 2789
26. Hofland L J, van der Hoek J, Feelders R et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol: 2005; 152 645 654
27. Boscaro M, Ludlam W H, Atkinson B et al. Treatment of pituitary-dependent Cushings disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab: 2009; 94 115 122
28. OCarroll A M, Krempels K. Widespread distribution of somatostatin receptor messenger ribonucleic acids in rat pituitary. Endocrinology: 1995; 136 5224 5227
29. Park S, Kamegai J, Kineman R D. Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1-sst5) mRNA levels: evidence for direct and somatostatin-mediated effects. Neuroendocrinology: 2003; 78 163 175
30. Panetta R, Patel Y C. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci: 1995; 56 333 342
31. Mato E, Matias-Guiu X, Chico A et al. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J Clin Endocrinol Metab: 1998; 83 2417 2420
32. Ain K B, Taylor K D, Tofiq S et al. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab: 1997; 82 1857 1862
33. Taniyama Y, Suzuki T, Mikami Y et al. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J: 2005; 52 605 611
34. Korner M, Eltschinger V, Waser B et al. Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. Am J Surg Pathol: 2005; 29 1642 1651
35. Orlando C, Raggi C C, Bianchi S et al. Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue. Endocr Relat Cancer: 2004; 11 323 332
36. Kumar U, Grigorakis S I, Watt H L et al. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat: 2005; 92 175 186
37. Prevost G, Foehrle E, Thomas F et al. Growth of human breast cancer cell lines is inhibited by the somatostatin analog BIM23014. Endocrinology: 1991; 129 323 329
38. Weckbecker G, Liu R, Tolcsvai L et al. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res: 1992; 52 4973 4978
39. Bajetta E, Procopio G, Ferrari L et al. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer: 2002; 94 299 304
40. Ruan W, Fahlbusch F, Clemmons D R et al. SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3? Mol Endocrinol: 2006; 20 426 436
41. Goddard I, Bauer S, Gougeon A et al. Somatostatin inhibits stem cell factor messenger RNA expression by Sertoli cells and stem cell factor-induced DNA synthesis in isolated seminiferous tubules. Biol Reprod: 2001; 65 1732 1742
42. Fombonne J, Csaba Z, von Boxberg Y et al. Expression of somatostatin receptor type-2 (sst2A) in immature porcine Leydig cells and a possible role in the local control of testosterone secretion. Reprod Biol Endocrinol: 2003; 1 19
43. Baou N, Bouras M, Droz J P et al. Evidence for a selective loss of somatostatin receptor subtype expression in male germ cell tumors of seminoma type. Carcinogenesis: 2000; 21 805 810
44. Fischer T, Doll C, Jacobs S et al. Reassessment of sst2 Somatostatin Receptor Expression in Human Normal and Neoplastic Tissues Using the Novel Rabbit Monoclonal Antibody UMB-1. J Clin Endocrinol Metab: 2008
45. Reynaert H, Rombouts K, Vandermonde A et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut: 2004; 53 1180 1189
46. Yamada Y, Post S R, Wang K et al. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA: 1992; 89 251 255
47. Raderer M, Hejna M H, Muller C et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol: 2000; 16 1197 1201
48. Blaker M, Schmitz M, Gocht A et al. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol: 2004; 41 112 118
49. Verhoef C, van Dekken H, Hofland L J et al. CH. Somatostatin receptor in human hepatocellular carcinomas: biological, patient and tumor characteristics. Dig Surg: 2008; 25 21 26
50. Balster D A, ODorisio M S, Summers M A et al. Segmental expression of somatostatin receptor subtypes sst(1) and sst(2) in tubules and glomeruli of human kidney. Am J Physiol Renal Physiol: 2001; 280 F457 F465
51. Bhandari S, Watson N, Long E et al. Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney. J Histochem Cytochem: 2008; 56 733 743
52. Reubi J C, Horisberger U, Studer U E et al. Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. J Clin Endocrinol Metab: 1993; 77 1323 1328
53. Rolleman E J, Kooij P P, de Herder W W et al. Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. Eur J Nucl Med Mol Imaging: 2007; 34 1854 1860
54. Freudenberg L S, Gauler T, Gorges R et al. Somatostatin receptor scintigraphy in advanced renal cell carcinoma. Results of a phase II-trial of somatostatine analogue therapy in patients with advanced RCC. Nuklearmedizin: 2008; 47 127 131
55. Smith W H, Nair R U, Adamson D et al. Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts. J Endocrinol: 2005; 187 379 386
56. Colao A, Marzullo P, Ferone D et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab: 2000; 85 3132 3140
57. Varecza Z, Elekes K, Laszlo T et al. Expression of the somatostatin receptor subtype 4 in intact and inflamed pulmonary tissues. J Histochem Cytochem: 2009; 57 1127 1137